Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 12/20 | 0.63 |
| ▸ | CDK2 | P24941 | 6/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.42 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.42 |
| ▸ | MAT2A | P31153 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.38 |
| ▸ | CDK7 | P50613 | 1/20 | 0.38 |
| ▸ | CCNH | P51946 | 1/20 | 0.38 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11930865 | 0.90 | GSK3B (0.65) | GSK3BCDK2CHEK1CCNA2CCNA1 | |
| SCHEMBL12952905 | 0.83 | GSK3B (0.65) | GSK3BCDK2CHEK1CCNA2CCNA1 | |
| SCHEMBL11930875 | 0.80 | CDK2 (0.64) | GSK3BCDK2CHEK1CCNA2CCNA1 | |
| SCHEMBL12953472 | 0.79 | GSK3B (0.70) | GSK3BCDK2CHEK1CCNA2CCNA1 | |
| SCHEMBL13116953 | 0.79 | GSK3B (0.67) | GSK3BCDK2CHEK1CCNA2CCNA1 | |
| SCHEMBL14545927 | 0.78 | GSK3B (0.43) | GSK3BCDK2CCNE1CDK7CCNH | |
| SCHEMBL11930874 | 0.78 | GSK3B (0.42) | GSK3BCDK2CCNE1CDK7CCNH | |
| SCHEMBL12952999 | 0.78 | GSK3B (0.68) | GSK3BCDK2CHEK1CCNA2CCNA1 | |
| SCHEMBL12952914 | 0.78 | GSK3B (1.00) | GSK3BCDK2CCNE1 | |
| SCHEMBL12953010 | 0.76 | GSK3B (0.63) | GSK3BCDK2CHEK1CCNA2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1942900-B1 | USE OF PYRAZOLO [1,5-A] PYRIMIDINE DERIVATIVES FOR INHIBITING KINASES METHODS FOR INHIBITING PROTEIN KINASES | MERCK SHARP & DOHME (US) | 2015-06-03 | — | — | EP | disclosed |
| US-8211854-B2 | Methods for inhibiting protein kinases | SCHERING CORPORATION (US) | 2012-07-03 | — | — | US | disclosed |
| US-8211854-B2 | Methods for inhibiting protein kinases | SCHERING CORPORATION (US) | 2012-07-03 | — | — | US | disclosed |
| US-20100125068-A1 | METHODS FOR INHIBITING PROTEIN KINASES | SCHERING CORPORATION | 2010-05-20 | — | — | US | disclosed |
| US-20100125068-A1 | METHODS FOR INHIBITING PROTEIN KINASES | SCHERING CORPORATION | 2010-05-20 | — | — | US | disclosed |
| WO-2007044441-A2 | USE OF PYRAZOLO [1 , 5 -A] PYRIMIDINE DERIVATIVES FOR INHIBITING PROTEIN KINASES METHODS FOR INHIBITING PROTEIN KINASES | SCHERING CORPORATION (US) | 2007-04-19 | — | — | WO | disclosed |
| US-20070082900-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-04-12 | — | — | US | disclosed |
| US-20070082900-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082900-A1 | Methods for inhibiting protein kinases | PIM1, AURKC, PIM3 | GSK3B 334/4885CDK2 64/4885CHEK1 8/4885 |
| US-20100125068-A1 | METHODS FOR INHIBITING PROTEIN KINASES | PIM1, AURKC, PIM3 | GSK3B 334/4885CDK2 64/4885CHEK1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.